Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 11/20 | 0.49 |
| ▸ | ADCY8 | P40145 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22668459 | 0.94 | ADCY1 (0.51) | ADCY1ADCY8POLBLMNAHTT | |
| SCHEMBL22668585 | 0.87 | ADCY1 (0.53) | ADCY1ADCY8POLBLMNAHTT | |
| SCHEMBL22668821 | 0.86 | ADCY1 (0.52) | ADCY1ADCY8POLBLMNAHTT | |
| SCHEMBL22668450 | 0.85 | ADCY1 (0.51) | ADCY1ADCY8POLBLMNAHTT | |
| SCHEMBL22668775 | 0.85 | ADCY1 (0.51) | ADCY1ADCY8POLBLMNAHTT | |
| SCHEMBL22668466 | 0.85 | ADCY1 (0.48) | ADCY1ADCY8LMNAHTTNPC1 | |
| SCHEMBL22668463 | 0.84 | ADCY1 (0.56) | ADCY1ADCY8POLBLMNAHTT | |
| SCHEMBL22668490 | 0.83 | ADCY1 (0.61) | ADCY1ADCY8POLBLMNAHTT | |
| SCHEMBL22668781 | 0.82 | ADCY1 (0.60) | ADCY1ADCY8POLBLMNAHTT | |
| SCHEMBL22668461 | 0.82 | ADCY1 (0.60) | ADCY1ADCY8POLBLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361882-A1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | MICROBIOTIX, INC. (US) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361882-A1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | RIOX2, MRPS35, AADAC | ADCY1 3421/4885ADCY8 3428/4885POLB 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.